The IASLC Lung Cancer Staging Project: Validation of the Proposals for Revision of the T, N, and M Descriptors and Consequent Stage Groupings in the Forthcoming.

Slides:

Advertisements

Similar presentations

The IASLC Lung Cancer Database Summary of Cases Contributed to Project Total cases submitted 100,869 Excluded from analyses Excluded from analyses19,854.

Advertisements

Small Cell Lung Cancer Clinical T-Stage, N0-N3 M0 SCLC From: Shepherd FA, Crowley J, Van Houtte P et al. The IASLC lung cancer staging project: proposals.

A2-06: Survival differences for non-Bronchioloalveolar Carcinoma (BAC) non-small-cell lung cancer (NSCLC) cases with ipsilateral intrapulmonary metastasis.

Assessment of Lymph Node Ratio to Replace the pN Categories System of Classification of the TNM System in Esophageal Squamous Cell Carcinoma Yingjie.

Primary Signet-Ring Carcinoma (SRC) of the Lung: A Population-Based Epidemiologic Study of 262 Cases with Comparison to Adenocarcinoma of the Lung Sai-Hong.

Carcinoma NOS is a Common Histologic Diagnosis and is Increasing in Proportion Among Non-small Cell Lung Cancer Histologies Sai-Hong Ignatius Ou, MD,

Which is the Better Prognostic Factor for Resected Non-small Cell Lung Cancer: The Number of Metastatic Lymph Nodes or the Currently Used Nodal Stage.

The eighth edition TNM stage classification for lung cancer: What does it mean on main street? Frank C. Detterbeck, MD The Journal of Thoracic and Cardiovascular.

The International Association for the Study of Lung Cancer Lung Cancer Staging Project: Proposals Regarding the Clinical Staging of Small Cell Lung Cancer.

Ratio of Metastatic Lymph Nodes to Total Number of Nodes Resected is Prognostic for Survival in Esophageal Carcinoma Clive J. Kelty, MB, ChB, PhD, FRCSEd,

Prognostic Significance of the Number of Lymph Nodes Removed at Lobectomy in Stage IA Non-small Cell Lung Cancer Sai-Hong Ignatius Ou, MD, PhD, Jason.

James B. Yu, MD, Lynn D. Wilson, MD, MPH, Frank C. Detterbeck, MD

The IASLC Lung Cancer Staging Project: Proposals for the Revision of the TNM Stage Groupings in the Forthcoming (Seventh) Edition of the TNM Classification.

Validation of the Stage Groupings in the Eighth Edition of the TNM Classification for Lung Cancer Xizhao Sui, MD, Wei Jiang, MD, Haiqing Chen, MD, Fan.

Nicolas Girard, MD, Julie Teruya-Feldstein, MD, Eden C

Complement and Correction for Meta-Analysis of Patients with Extensive-Stage Small Cell Lung Cancer Managed with Irinotecan/Cisplatin versus Etoposide/Cisplatin.

Verification of the Newly Proposed T Category (Seventh Edition of the Tumor, Node, and Metastasis Classification) from a Clinicopathological Viewpoint.

The IASLC Lung Cancer Staging Project: Proposals Regarding the Relevance of TNM in the Pathologic Staging of Small Cell Lung Cancer in the Forthcoming.

Gemcitabine and Irinotecan for Patients with Untreated Extensive Stage Small Cell Lung Cancer: SWOG 0119 Wallace Akerley, MD, Jason McCoy, MS, Paul J.

The IASLC Lung Cancer Staging Project: The New Database to Inform the Eighth Edition of the TNM Classification of Lung Cancer Ramón Rami-Porta, MD, FETCS,

Electronic Updates for JTO Readers

IA05.01 Lung Cancer Cases Journal of Thoracic Oncology

Lymph Node Ratio May Predict the Benefit of Postoperative Radiotherapy in Non– Small-Cell Lung Cancer Damien Urban, MBBS, B Med Sc, Jair Bar, MD, PhD,

John E. Pilling, FRCS (CTh), Michael E

The International Association for the Study of Lung Cancer International Staging Project on Lung Cancer Peter Goldstraw, MB, FRCS, John J. Crowley, PhD

Samuel J. Wang, MD, PhD, C David Fuller, MD, Charles R. Thomas, MD

Which is the Better Prognostic Factor for Resected Non-small Cell Lung Cancer: The Number of Metastatic Lymph Nodes or the Currently Used Nodal Stage.

Frank Detterbeck, MD Journal of Thoracic Oncology

Central versus Peripheral Tumor Location: Influence on Survival, Local Control, and Toxicity Following Stereotactic Body Radiotherapy for Primary Non–Small-Cell.

Mediastinal Lymph Node Examination and Survival in Resected Early-Stage Non– Small-Cell Lung Cancer in the Surveillance, Epidemiology, and End Results.

An Updated Meta-Analysis of Randomized Controlled Trials Comparing Irinotecan/Platinum with Etoposide/Platinum in Patients with Previously Untreated.

Intratumoral Lymphatic Vessel Involvement is an Invasive Indicator of Completely Resected Pathologic Stage I Non-small Cell Lung Cancer Masahiko Harada,

Effects of Chemotherapy on Survival of Elderly Patients with Small-Cell Lung Cancer: Analysis of the SEER-Medicare Database Laura C. Caprario, MD, MS,

The Applicability of the Proposed IASLC Staging Revisions to Small Cell Lung Cancer (SCLC) with Comparison to the Current UICC 6th TNM Edition Sai-Hong.

Ellen Kim, MD, MPH, Siran Koroukian, PhD, Charles R. Thomas, MD

The IASLC Lung Cancer Staging Project: Proposals for the Revision of the T Descriptors in the Forthcoming (Seventh) Edition of the TNM Classification.

Chemotherapy in Patients ≥80 with Advanced Non-small Cell Lung Cancer: Combined Results from SWOG 0027 and LUN 6 Paul J. Hesketh, MD, Rogerio C. Lilenbaum,

Daniel Morgensztern, MD, Boone Goodgame, MD, Maria Q

Assessment of Lymph Node Ratio to Replace the pN Categories System of Classification of the TNM System in Esophageal Squamous Cell Carcinoma Yingjie.

Clinical Utility of the Pretreatment Glasgow Prognostic Score in Patients with Advanced Inoperable Non-small Cell Lung Cancer Elaine Y.L. Leung, MB ChB,

Trends in Stage Distribution for Patients with Non-small Cell Lung Cancer: A National Cancer Database Survey Daniel Morgensztern, MD, Shean Huey Ng,

The IASLC Lung Cancer Staging Project: Proposals for the Revisions of the T Descriptors in the Forthcoming Eighth Edition of the TNM Classification for.

Multiple Primary Cancers or Multiple Metastases, That Is the Question

The IASLC Lung Cancer Staging Project: Proposals for the Inclusion of Broncho- Pulmonary Carcinoid Tumors in the Forthcoming (Seventh) Edition of the TNM.

Conditional Survival of Malignant Thymoma Using National Population-Based Surveillance, Epidemiology, and End Results (SEER) Registry (1973–2011) Ellen.

Frequency and Prognostic Significance of Preoperatively Detected Enlarged Regional Lymph Nodes in Patients with Pathological Stage I Non-small Cell Lung.

It’s All in the “Swerve of the Curve”

A2-06: Survival differences for non-Bronchioloalveolar Carcinoma (BAC) non-small-cell lung cancer (NSCLC) cases with ipsilateral intrapulmonary metastasis.

Immune-Modulating Vaccines in Non-small Cell Lung Cancer

Validation of the Proposed International Association for the Study of Lung Cancer Non- small Cell Lung Cancer Staging System Revisions for Advanced Bronchioloalveolar.

Visceral Pleura Invasion Impact on Non-small Cell Lung Cancer Patient Survival: Its Implications for the Forthcoming TNM Staging Based on a Large-Scale.

MINI01.08: Disparities in the Management of Patients with Stage I Small Cell Lung Cancer (SCLC): A Surveillance, Epidemiology and End Results (SEER) Analysis

Genetic Changes in Squamous Cell Lung Cancer: A Review

Ethnic Differences in the Management of Lung Cancer in New Zealand

Clinical and Pathological Staging Validation in the Eighth Edition of the TNM Classification for Lung Cancer: Correlation between Solid Size on Thin-Section.

International Thymic Malignancies Interest Group: A Way Forward

Stage I Non-small Cell Lung Cancer: Results for Surgery in a Patterns-of-Care Study in Sydney and for High-Dose Concurrent End-Phase Boost Accelerated.

Validity of International Association for the Study of Lung Cancer Proposals for the Revision of N Descriptors in Lung Cancer Jin Gu Lee, MD, Chang Young.

Wedge Resection for Non-small Cell Lung Cancer in Patients with Pulmonary Insufficiency: Prospective Ten-Year Survival John P. Griffin, MD, Charles E.

Epidemiology of Thymoma and Associated Malignancies

Should the 7th Edition of the Lung Cancer Stage Classification System Change Treatment Algorithms in Non-small Cell Lung Cancer? Daniel J. Boffa, MD,

Surveillance Epidemiology and End Results Evaluation of the Role of Surgery for Stage I Small Cell Lung Cancer James B. Yu, MD, Roy H. Decker, MD, PhD,

Concurrent Chemotherapy and Short Course Radiotherapy in Patients with Stage IIIA to IIIB Non-small Cell Lung Cancer Not Eligible for Radical Treatment:

Rogerio C. Lilenbaum, MD, John Cashy, PhD, Thomas A

The IASLC Lung Cancer Staging Project

A Review of First-Line Treatment for Small-cell Lung Cancer

Long-Term Follow-Up of a Phase I/II Trial of Dose Escalating Three-Dimensional Conformal Thoracic Radiation Therapy with Induction and Concurrent Carboplatin.

Prognostic Significance of Tumor Size in Patients with Stage III Non–Small-Cell Lung Cancer: A Surveillance, Epidemiology, and End Results (SEER) Survey.

Node-Negative Non-small Cell Lung Cancer: Pathological Staging and Survival in 1765 Consecutive Cases Benjamin M. Robinson, BSc, MBBS, Catherine Kennedy,

Reply to “Influence of Body Mass Index on Overall Survival Following Surgical Resection of Non–Small Cell Lung Cancer: Methodological Issues” Boris Sepesi,

Presentation transcript:

The IASLC Lung Cancer Staging Project: Validation of the Proposals for Revision of the T, N, and M Descriptors and Consequent Stage Groupings in the Forthcoming (Seventh) Edition of the TNM Classification of Malignant Tumours Patti A. Groome, PhD, Vanessa Bolejack, MPH, John J. Crowley, PhD, Catherine Kennedy, RMRA, Mark Krasnik, MD, Leslie H. Sobin, MD, Peter Goldstraw, FRCS Journal of Thoracic Oncology Volume 2, Issue 8, Pages 694-705 (August 2007) DOI: 10.1097/JTO.0b013e31812d05d5 Copyright © 2007 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 1 Stage distribution by continent non-small cell lung cancer (A) and small-cell lung cancer (B). Journal of Thoracic Oncology 2007 2, 694-705DOI: (10.1097/JTO.0b013e31812d05d5) Copyright © 2007 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 2 Overall survival of T1–T3 N0 by size of tumor in the Surveillance, Epidemiology, and End Results Program and results of pairwise comparisons. HR, hazard ratio. Journal of Thoracic Oncology 2007 2, 694-705DOI: (10.1097/JTO.0b013e31812d05d5) Copyright © 2007 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 3 Overall survival of T3–T4 or M1 by same-side nodules in the Surveillance, Epidemiology, and End Results Program and results of pairwise comparisons. Journal of Thoracic Oncology 2007 2, 694-705DOI: (10.1097/JTO.0b013e31812d05d5) Copyright © 2007 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 4 Overall survival by TNM sixth edition N category in Surveillance, Epidemiology, and End Results Program (SEER) and results of pairwise comparisons. Journal of Thoracic Oncology 2007 2, 694-705DOI: (10.1097/JTO.0b013e31812d05d5) Copyright © 2007 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 5 Overall survival of T4 and M1 minus same-side nodules in Surveillance, Epidemiology, and End Results Program (SEER) and results of pairwise comparisons. Journal of Thoracic Oncology 2007 2, 694-705DOI: (10.1097/JTO.0b013e31812d05d5) Copyright © 2007 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 6 Overall survival by proposed TNM stage groupings, validation data set, clinical stage (A), and pathologic stage (B). Journal of Thoracic Oncology 2007 2, 694-705DOI: (10.1097/JTO.0b013e31812d05d5) Copyright © 2007 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 7 Overall survival by best stage in SEER: TNM sixth edition (A) and IASLC proposed (B). Journal of Thoracic Oncology 2007 2, 694-705DOI: (10.1097/JTO.0b013e31812d05d5) Copyright © 2007 International Association for the Study of Lung Cancer Terms and Conditions